These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

717 related articles for article (PubMed ID: 23399552)

  • 1. GI-REASONS: a novel 6-month, prospective, randomized, open-label, blinded endpoint (PROBE) trial.
    Cryer B; Li C; Simon LS; Singh G; Stillman MJ; Berger MF
    Am J Gastroenterol; 2013 Mar; 108(3):392-400. PubMed ID: 23399552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-level pooled analysis of adjudicated gastrointestinal outcomes in celecoxib clinical trials: meta-analysis of 51,000 patients enrolled in 52 randomized trials.
    Moore A; Makinson G; Li C
    Arthritis Res Ther; 2013 Jan; 15(1):R6. PubMed ID: 23298471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT).
    MacDonald TM; Hawkey CJ; Ford I; McMurray JJV; Scheiman JM; Hallas J; Findlay E; Grobbee DE; Hobbs FDR; Ralston SH; Reid DM; Walters MR; Webster J; Ruschitzka F; Ritchie LD; Perez-Gutthann S; Connolly E; Greenlaw N; Wilson A; Wei L; Mackenzie IS
    Eur Heart J; 2017 Jun; 38(23):1843-1850. PubMed ID: 27705888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of celecoxib versus diclofenac and omeprazole in elderly arthritis patients: a subgroup analysis of the CONDOR trial.
    Kellner HL; Li C; Essex MN
    Curr Med Res Opin; 2012 Sep; 28(9):1537-45. PubMed ID: 22852870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
    Silverstein FE; Faich G; Goldstein JL; Simon LS; Pincus T; Whelton A; Makuch R; Eisen G; Agrawal NM; Stenson WF; Burr AM; Zhao WW; Kent JD; Lefkowith JB; Verburg KM; Geis GS
    JAMA; 2000 Sep; 284(10):1247-55. PubMed ID: 10979111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The APC and PreSAP trials: a post hoc noninferiority analysis using a comprehensive new measure for gastrointestinal tract injury in 2 randomized, double-blind studies comparing celecoxib and placebo.
    Arber N; Lieberman D; Wang TC; Zhang R; Sands GH; Bertagnolli MM; Hawk ET; Eagle C; Coindreau J; Zauber A; Lanas A; Levin B
    Clin Ther; 2012 Mar; 34(3):569-79. PubMed ID: 22386831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of celecoxib compared with placebo and non-selective NSAIDs: cumulative meta-analysis of 89 randomized controlled trials.
    Essex MN; Zhang RY; Berger MF; Upadhyay S; Park PW
    Expert Opin Drug Saf; 2013 Jul; 12(4):465-77. PubMed ID: 23506230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and possible risk factors for clinical upper gastrointestinal events in patients taking selective cyclooxygenase-2 inhibitors: A prospective, observational, cohort study in Taiwan.
    Hsiang KW; Chen TS; Lin HY; Luo JC; Lu CL; Lin HC; Lee KC; Chang FY; Lee SD
    Clin Ther; 2010 Jul; 32(7):1294-303. PubMed ID: 20678677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-utility of celecoxib use in different treatment strategies for osteoarthritis and rheumatoid arthritis from the Quebec healthcare system perspective.
    Bessette L; Risebrough N; Mittmann N; Roussy JP; Ho J; Zlateva G
    J Med Econ; 2009 Sep; 12(3):246-58. PubMed ID: 19743942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pooled analysis of GI tolerability of 21 randomized controlled trials of celecoxib and nonselective NSAIDs.
    Niculescu L; Li C; Huang J; Mallen S
    Curr Med Res Opin; 2009 Mar; 25(3):729-40. PubMed ID: 19210159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gastrointestinal tolerability of NSAIDs in elderly patients: a pooled analysis of 21 randomized clinical trials with celecoxib and nonselective NSAIDs.
    Mallen SR; Essex MN; Zhang R
    Curr Med Res Opin; 2011 Jul; 27(7):1359-66. PubMed ID: 21561397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.
    McCormack PL
    Drugs; 2011 Dec; 71(18):2457-89. PubMed ID: 22141388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
    Lai KC; Chu KM; Hui WM; Wong BC; Hu WH; Wong WM; Chan AO; Wong J; Lam SK
    Am J Med; 2005 Nov; 118(11):1271-8. PubMed ID: 16271912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
    Chen YF; Jobanputra P; Barton P; Bryan S; Fry-Smith A; Harris G; Taylor RS
    Health Technol Assess; 2008 Apr; 12(11):1-278, iii. PubMed ID: 18405470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial.
    Chan FK; Lanas A; Scheiman J; Berger MF; Nguyen H; Goldstein JL
    Lancet; 2010 Jul; 376(9736):173-9. PubMed ID: 20638563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy of rebamipide add-on therapy in arthritic patients with COX-2 selective inhibitor-related gastrointestinal events: a prospective, randomized, open-label blinded-endpoint pilot study by the GLORIA study group.
    Hasegawa M; Horiki N; Tanaka K; Wakabayashi H; Tano S; Katsurahara M; Uchida A; Takei Y; Sudo A
    Mod Rheumatol; 2013 Nov; 23(6):1172-8. PubMed ID: 23306427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of hospitalization for upper gastrointestinal adverse events associated with nonsteroidal anti-inflammatory drugs: a nationwide case-crossover study in Taiwan.
    Chang CH; Chen HC; Lin JW; Kuo CW; Shau WY; Lai MS
    Pharmacoepidemiol Drug Saf; 2011 Jul; 20(7):763-71. PubMed ID: 21618340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of celecoxib and nonselective nonsteroidal anti-inflammatory drugs in juvenile idiopathic arthritis: results of the Phase 4 registry.
    Sobel RE; Lovell DJ; Brunner HI; Weiss JE; Morris PW; Gottlieb BS; Chalom EC; Jung LK; Onel KB; Petiniot L; Goldsmith DP; Nanda K; Shishov M; Abramsky S; Young JP; Giannini EH;
    Pediatr Rheumatol Online J; 2014; 12():29. PubMed ID: 25057265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.
    Hochberg MC
    Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S15-22. PubMed ID: 11695246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study.
    Singh G; Fort JG; Goldstein JL; Levy RA; Hanrahan PS; Bello AE; Andrade-Ortega L; Wallemark C; Agrawal NM; Eisen GM; Stenson WF; Triadafilopoulos G;
    Am J Med; 2006 Mar; 119(3):255-66. PubMed ID: 16490472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.